PLX.TA - Protalix BioTherapeutics, Inc.

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
173.50
-2.20 (-1.25%)
At close: 5:24PM IDT
Stock chart is not supported by your current browser
Previous Close175.70
Open174.00
Bid173.50 x 128000
Ask173.90 x 209400
Day's Range173.00 - 176.40
52 Week Range143.60 - 325.00
Volume183,489
Avg. Volume247,627
Market Cap246.767M
Beta1.15
PE Ratio (TTM)N/A
EPS (TTM)-0.26
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire5 days ago

    Protalix BioTherapeutics Appoints David Granot to its Board of Directors

    Protalix BioTherapeutics, Inc. (NYSE American: PLX, TASE: PLX), announced today that the Company’s Board of Directors has appointed Mr. David Granot to serve on the Company’s Board of Directors, effective on August 9, 2018.  In addition to Mr. Granot’s appointment as an independent director, he was also appointed to serve on the Company’s Audit Committee.

  • Protalix (PLX) Reports Q2 Loss, Misses Revenue Estimates
    Zacks9 days ago

    Protalix (PLX) Reports Q2 Loss, Misses Revenue Estimates

    Protalix (PLX) delivered earnings and revenue surprises of -33.33% and -71.34%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Who Owns Protalix BioTherapeutics Inc (NYSEMKT:PLX)?
    Simply Wall St.9 days ago

    Who Owns Protalix BioTherapeutics Inc (NYSEMKT:PLX)?

    In this article, I will take a quick look at Protalix BioTherapeutics Inc’s (NYSEMKT:PLX) recent ownership structure – an unconventional investing subject, but an important one. The impact of aRead More...

  • Associated Press9 days ago

    Protalix: 2Q Earnings Snapshot

    On a per-share basis, the Carmiel, Israel-based company said it had a loss of 8 cents. The drug developer posted revenue of $2 million in the period. The company's shares closed at 50 cents. A year ago, ...

  • GlobeNewswire9 days ago

    Protalix BioTherapeutics Reports 2018 Second Quarter Results and Provides Corporate Update

    CARMIEL, Israel, Aug. 09, 2018-- Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary ...

  • GlobeNewswire18 days ago

    Protalix BioTherapeutics to Hold Second Quarter 2018 Financial Results and Corporate Update Conference Call on August 9, 2018

    CARMIEL, Israel, July 31, 2018-- Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary ...

  • Benzinga25 days ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Protalix Biotherapeutics Inc (NYSE: PLX ) stock gained ...

  • GlobeNewswire25 days ago

    Protalix BioTherapeutics Expands Partnership with Chiesi Farmaceutici to Include Exclusive U.S. Rights for the Development and Commercialization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease

    Protalix BioTherapeutics, Inc. (NYSE American:PLX) (PLX.TA), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced the expansion of its partnership with Chiesi Farmaceutici S.p.A., or Chiesi. Protalix and Chiesi entered into an exclusive U.S. license and supply agreement which grants to Chiesi the United States rights for the development and commercialization of PRX-102 (pegunigalsidase alfa), the Company’s chemically modified version of the recombinant protein alpha-Galactosidase-A protein, for the treatment of Fabry disease.

  • GlobeNewswire2 months ago

    Protalix BioTherapeutics Announces Additional Positive Results from Final Analysis of the Phase II Clinical Trial of OPRX-106 for the Treatment of Ulcerative Colitis

    Mucosal Improvement Observed in 61% of the Patients and 33% achieved Mucosal Healing. Clinical Responses Observed in 67% of the Patients and Clinical Remission Observed in 28% of the Patients. 89% of the ...

  • GlobeNewswire3 months ago

    Protalix BioTherapeutics Announces Poster Presentation on Baseline Characteristics for Fabry Disease Patients Screened in the Phase III BALANCE Study of Pegunigalsidase Alfa at the 55th ERA-EDTA Congress

    GlobeNewswire /Protalix BioTherapeutics, Inc. (NYSE American:PLX) (PLX.TA), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that a poster presentation on the characteristics of Fabry disease patients screened in the phase III BALANCE clinical trial of pegunigalsidase alfa, a PEGylated alfa galactosidase alfa enzyme, or PRX-102, for the treatment of Fabry disease was presented at the 55th ERA-EDTA Congress (European Renal Association – European Dialysis and Transplant Association).

  • GlobeNewswire3 months ago

    Protalix Announces Exchange and Discharge of Remaining 2018 Notes

    Protalix BioTherapeutics, Inc. (the “Company”) (NYSE American:PLX) (PLX.TA) announced today that $3.42 million of the aggregate principal amount of the Company’s outstanding 4.5% Convertible Senior Notes due 2018 (the “Notes”) will be exchanged for 2,613,636 shares of the Company’s common stock and $2.27 million in cash.  Additionally, the Company announced today that it has delivered the necessary funds under the indenture governing the Notes to effectively discharge the remaining outstanding Notes.  Additional details regarding the exchange can be found in the Company’s Form 8-K to be filed with the Securities and Exchange Commission.

  • Associated Press3 months ago

    Protalix: 1Q Earnings Snapshot

    The Carmiel, Israel-based company said it had a loss of 6 cents per share. The drug developer posted revenue of $4.6 million in the period. The company's shares closed at 40 cents. A year ago, they were ...

  • Benzinga5 months ago

    Benzinga Pro's 5 Stock To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Athersys, Inc. (NASDAQ: ATHX ) stock gained more than ...

  • Protalix BioTherapeutics Inc (NYSEMKT:PLX): Are Analysts Optimistic?
    Simply Wall St.5 months ago

    Protalix BioTherapeutics Inc (NYSEMKT:PLX): Are Analysts Optimistic?

    Protalix BioTherapeutics Inc’s (AMEX:PLX): Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in IsraelRead More...

  • SmarterAnalyst7 months ago

    Company Update (NYSE:PLX): Protalix Biotherapeutics Inc Shares Fly 10% Following Impressive Phase II Interim Data in Ulcerative Colitis

    Protalix Biotherapeutics Inc (NYSE:PLX) stock is riding a nearly 10% gain this morning after the Israeli biotech firm unleashed positive interim data from its Phase II clinical study in ulcerative colitis (UC). The trial is investigating the company's oral anti-TNF drug OPRX-106, with data set loose from the first 14 patients who have completed the randomized, open label, two-arm study. A total of 24 patients were enrolled and randomized to receive 2 mg or 8 mg of OPRX-106, administered orally, once daily, for 8 weeks.  The first 14 patients have completed the study, and four patients are currently in treatment and follow-up.  The trial evaluated key efficacy endpoints including clinical response and remission utilizing the Mayo score, as well as safety and pharmacokinetics.